Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Healthy Returns: Why people quit weight loss, diabetes drugs within one year
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...
It's going to be harder to get weight loss jabs now - here's why
Previously, the drugs were able to be prescribed through an email chat, from questionnaires or by people sending in photos of ...
health.wusf.usf.edu1d
About half of Americans approve of using weight-loss drugs to treat obesity, a poll finds
The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...
Medicare Change Backed by 20,000 People in New Letters
New letters urge the Centers for Medicare & Medicaid Services to expand Medicare and Medicaid to include FDA-approved ...
Best Health Care Stocks to Watch in February 2025
Some of the best health care stocks for February 2025, based on 30-day returns, include Akero Therapeutics Inc., Guardant Health Inc., and Inari Medical Inc. The best-performing health care stocks in ...
Here's why researchers think most people stop taking weight loss drugs within a year
Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...